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ABSTRACT 
 
Breast cancer (BC) is the most common type of cancer worldwide, being one of the leading causes of morbidity in 
the female. In Nepal, it is the second most common type of cancer among women of perimenopausal age group. 
More than one-quarter of the BC is diagnosed in young Nepalese female, with a familial history of breast cancer, 
early pregnancy, longer lactation and estrogen exposure, often tumors showing aggressive biological behaviors. An-
thracyclines (Doxorubicin) based treatment regime were reported to cause cardiotoxicity by increasing intramyocar-
dial free radical production, lipid alterations and decreasing antioxidant level. Oxidative stress involving cellular 
reactive oxygen species (ROS) production is widely accepted mechanism, but the molecular basis of chemotherapy-
induced organ toxicity remains highly controversial. An increased rate of metabolism and oxidative stress results in 
rapid turnover of cancer cells that modulates the enzyme level in blood circulation. Serum LDH and GGT level 
correlate with tumor burden, the metastatic character of BC and intensity of organtoxicity. The aim of our study is 
to evaluate the serum level of LDH and GGT in BC patients receiving chemotherapy and correlate these enzyme 
levels with different stages of BC. A total number of 150 subjects were included in the study, comprising 90 histo-
pathologically confirmed 24 to 76 years aged patients of different breast cancer stages, receiving at least 3 cycles of 
5-Fluorouracil, Adriamycin, and Cyclophosphamide (FAC) chemotherapy. Sixty age- matched healthy women were 
enrolled as controls. Blood samples from each were collected after informed consent and analyzed for serum LDH 
and GGT levels using standard biochemical methods. Data were analyzed using student's paired-T test, Pearson 
correlation test and ANOVA. Serum LDH and GGT levels were significantly (p < 0.001) increased in BC patients 
as compared to control group. When all 4 stages of BC were compared to control group, LDH and GGT activities 
showed a progressive increase from stage I to IV. The study concludes that serum LDH and GGT may be sensitive, 
specific and profitable biomarkers in early diagnosis of breast cancer, assessing cancer prognosis and response to 
treatment. 
 
Keywords: Breast cancer, stages, chemotherapy, Lactate dehydrogenase, Gamma glutamyl transpeptidase 
 
INTRODUCTION 
Breast cancer (BC) is the common type of cancers 
among women and has become the major public health 
problem worldwide [1, 2].  It was estimated that over 
five hundred thousand women died in 2011 due to 
breast cancer [3]. Among Nepalese women, BC is the 
second most common type of cancer that accounts for 
6% of total cancers in Nepal [4]. Familial history of BC, 
mutations on tumor suppressor genes like BRCA1, 
BRCA2 and p53 and reproductive factors associated 
with longer exposure to estrogen such as early menar-
che, late menopause, late age at first childbirth, oral con-
traceptives use and hormone replacement therapy in-
creases BC risk [1].  Nepalese young women represent 
more than one-quarter of the BC diagnosed in Nepal, 
often diagnosed at an advanced stage with tumors show-
ing aggressive biological behaviors [5]. Nearly 50% of 
BC patients will develop distant metastasis, and at some 
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point, more than half patients with metastatic BC will 
have liver involvement [6]. An increased rate of meta-
bolic changes like anaerobic glycolysis and oxidative 
stress results in a rapid turnover of cancer cells that 
modulates the enzyme level in blood circulation [7].  
Lactate dehydrogenase (LDH) is an enzyme of an-
aerobic glycolysis released into surrounding environ-
ment at increased rate when cells replicate rapidly [8]. 
LDH activity correlates with tumor burden, and the 
metastatic BC exhibits elevated LDH level than normal 
breast tissue [7]. Gamma Glutamyl transpeptidase 
(GGT) is an enzyme of glutathione metabolism, in-
volved in cell's detoxification pathway and apoptotic bal-
ance- including tumor development, progression and 
chemotherapy resistance [9, 10].  
5-Fluorouracil, doxorubicin, and cyclophosphamide 
(FAC) is the most common combination of chemother-
apy drugs used in breast cancer treatment that is often 
associated with oxidative stress, hepatotoxicity and car-
diotoxicity [11]. Elevated levels of cardiac enzymes LDH 
and creatine kinase (CK) after FAC treatment is evi-
dence of the cardiotoxic effect of chemotherapy [12]. 
Similarly, elevated serum GGT level is the markers for 
oxidative stress resulting from carcinomas with liver in-
volvement and liver toxicity [13]. 
Although oxidative stress involving cellular reactive 
oxygen species (ROS) production is widely accepted, the 
molecular mechanism of chemotherapy-induced organ 
toxicity remains highly controversial. Therefore the pre-
sent study was carried out to evaluate the serum levels 
of LDH and GGT in BC patients, of Nepal, receiving 
chemotherapy and correlate these organ toxicity mark-
ers with different stages of BC. 
 
MATERIALS AND METHODS 
Study design 
The present hospital based cross-sectional study was 
conducted at Department of Pathology, Bhaktapur Can-
cer Hospital (BCH), Bhaktapur, Nepal from September 
2013 to February 2015 and the study was approved by 
Ethical Review Board of Nepal Health Research Council 
(NHRC). The study subjects were divided into two 
groups; BC patients receiving chemotherapy and con-
trols group.  
 
Study subjects 
The study subjects comprised 90 clinically and his-
topathologically confirmed breast cancer patients of age 
24 to 76 years, receiving at least 3 cycles of 5-fluoroura-
cil, doxorubicin, and cyclophosphamide (FAC) chemo- 
therapy whereas control group consisted 60 normal 
healthy females of same age group. Breast cancer pa-
tients with the previous history of tuberculosis, rheu-
matic fever, diabetes, hypertension, hepatobiliary disease 
or myocardial infractions were excluded.  Informed con-
sent from each individuals was taken before blood sam-
ple, and other demographic information were collected. 
 
Histopathological grading 
The patients selected for the study were divided into 
4 different groups based on their tumor stages, stage I 
(n = 9), stage II (n = 31), stage III (n = 27) and stage IV 
(n = 23). Based on the Nottingham modification of the 
Scarff Bloom and Richardson's (SBR) grading system 
and TNM staging, tumor grades and stages were deter-
mined (where T describes the size of a tumor, N de-
scribes number of nodes involved and M describes me-
tastasis [14]. 
 
Sample analysis 
About 3 mL of blood sample was collected from the 
antecubital vein, allowed to clot and centrifuged at 3000 
rpm for 10 minutes to obtain the serum. Serum samples 
were then stored at -20°C until analyzed.  
Serum level of LDH was determined by catalyzing 
reaction between pyruvate and NADH to produce NAD 
and lactate measuring absorbance at 340 nm. Using 
semi-automated analyzer (Stat Fax 3300, USA). Simi-
larly, serum GGT level was estimated by measuring the 
amount of 5-amino-2-nitrobenzonate released during 
the catalytic reaction of L-γ-Glutamyl-3carboxy-4-ni-
troanilide with glycylglycine at 405 nm. Enzyme levels 
were determined using Analyticon reagent kits (Analyt-
icon Biotechnologies AG Muhlenberg, Germany) on the 
semi-automated analyzer (Stat Fax 3300, USA). 
 
Statistical analyses 
The data obtained from biochemical analyses was 
tabulated and analyzed in Statistical Package for the So-
cial Sciences version 17 (SPSS, Chicago, IL). Means and 
standard deviations of LDH and GGT were calculated 
for pre and postmenopausal patients with different can-
cer stages. One way ANOVA was used for multiple 
group comparison. Pearson correlation (p) was used to 
measure the relationship between parameters and p - 
value of 0.05 or less was considered statistically signifi-
cant. 
 
RESULTS AND DISCUSSION 
In this study, serum LDH and GGT level was sig- 
 Anil S Basnyat, Abhimanyu Jha, R Pathak, Bhupal G Shrestha, 2017 
 
 
 JTLS | J. Trop. Life. Science 130 Volume 7 | Number 2 | April | 2017 
nificantly higher in pre and postmenopausal breast can-
cer patients when compared with controls (p < 0.05). 
Postmenopausal BC women showed higher LDH level 
than premenopausal women but in the case of serum 
GGT premenopausal women showed significantly in-
creased level as compared to postmenopausal as shown 
in [Table 1]. 
Pearson correlation coefficient (r = 0.622) showed 
the positive correlation between LDH and GGT in BC 
patients receiving chemotherapy. Serum LDH and GGT 
levels when compared in different stages of BC, the sig-
nificant rise was observed with increased disease severity 
(stage). One way ANOVA did not show significant dif-
ferences between the various stages of BC as shown in 
[Table 3]. 
Breast cancer that is detected in them early stage 
can be cured when the tumor is small enough which can 
be surgically removed completely [15]. Unfortunately, 
most cancers do not show any symptoms until tumors 
are either too large to remove surgically or cancerous 
cells have already spread to other organs [16]. 
In present study, serum LDH level was significantly 
(p < 0.001) increased in BC patients (mean 531.66 ± 
138.86 U/L) as compared to controls (mean 375.27 ± 
60.34 U/L) but further increased level was observed in 
postmenopausal women (543.22 ± 15.53 U/L). A mark-
edly increased LDH level was seen in postmenopausal 
BC patients than in premenopausal as similar to our 
finding [13, 17]. A significant rise in LDH level was ob-
served in BC patients than fibroadenoma patients [16]. 
Guddanti et al. [17] reported due to aggressive tumor 
growth; serum LDH level was observed significantly el-
evated in BC cases than in controls. Serum LDH levels 
when compared in different stages of BC, the significant 
rise was observed with increased disease severity (stage) 
similar to the study by Chandrakanth et al. [16]. A study 
by Bogdavonic et al. [7] observed LDH activity in stage 
IIIB patient was approximately 2 fold higher as com-
pared to lower stage samples. 
Serum LDH was significantly increased in preoper-
ative BC patients with and without lymph node metas-
tasis in comparison to controls [8]. Similarly, Cao et al. 
[6] reported LDH levels were significantly higher in BC 
patients with liver metastasis than those without liver 
metastasis. An elevated serum LDH enzyme activity is 
the consequence of increased anaerobic glycolysis in rap-
idly dividing malignant cells and subsequent cell de-
struction [18].  Increased level of serum LDH suggests 
the increase rate of enzyme leakage from mitochondria 
as a result of doxorubicin-induced toxicity [11]. A study 
by Basnyat et al. [19] reported that elevated serum lipids 
level increased the risk of cardiovascular disease during 
BC management by FAC combination. 
GGT is a membrane-bound enzyme involved in the 
metabolism of glutathione, a non-protein thiol molecule 
that protects cells against oxidative stress [15]. GGT is 
crucially involved in cell's detoxification pathway and 
apoptotic balance- including tumor development, pro-
gression and chemotherapy resistance [9, 10]. An ele-
vated GGT level significantly increased the risk of devel-
oping neoplasms of breast, female genital organs, diges-
tive organs, lymphoid and hematopoietic cancers [20]. 
Similarly, Grimm et al. [9] reported elevated serum 
GGT level is associated with increased cancer risk and 
worse prognosis of gynecologic cancers.  
In this study, we found significantly (p<0.001) in-
creased serum GGT level in BC patients (mean 64.71 ± 
26.16 U/L) as compared to controls (27.00 ± 13.12 U/L), 
but the further increased level was observed in premen-
opausal BC women (64.82 ± 26.10 U/L). A study by Ja-
rari et al. [13] reported significantly higher level of se-
rum GGT in breast cancer cases as compared to con-
trols, but the significant hike was observed in the 
premenopausal group when compared with that of post 
Table 1. Distribution of serum LDH and GGT level in controls, premenopausal and postmenopausal BC patients 
Parameters Menstrual status Controls  (n = 60) Patients (n = 90) p value 
LDH (U/L) Premenopausal 370.88 ± 64.92 532.99 ± 138.58 0.013 
Postmenopausal 384.05 ± 50.39 543.22 ± 15.53 0.007 
GGT (U/L) Premenopausal 26.08 ± 12.76 64.82 ± 26.10 0.030 
Postmenopausal 28.85 ± 13.99 64.44 ± 23.92 0.093 
 
Table 2. Overall distribution of LDH and GGT level in BC patients and controls 
Parameters Controls Patients p value 
LDH (U/L) 375.27 ± 60.34 531.66 ± 138.86 p < 0.001 
GGT (U/L) 27.00 ± 13.12 64.71 ± 26.16 p < 0.001 
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menopausal similar to our findings. In contrast to our 
study, increased GGT level was observed in postmeno-
pausal breast cancer patients as compared to premeno-
pausal age group [17, 21].   
Serum GGT level when compared with patients 
having different stages of BC, we found proportional in-
creased GGT level from stage I to stage IV and the find-
ing was similar to the study by Chandrakanth et al. [16]. 
Choudhari et al. [15] also observed significantly in-
creased serum GGT level in all four stages of breast can-
cer patients as compared to controls, and interstage 
comparison showed a progressive increase from stage I-
IV as similar to our study.  Serum GGT level was signif-
icantly higher in patients with liver metastasis than with-
out liver metastasis [6]. An increased GGT expression is 
often seen in malignant and large sized tumors as com-
pared to smaller tumors [22]. Furthermore, GGT ex-
pression is increased as a response to oxidative stress 
which causes induction of GGT mRNAs by multiple sig-
naling pathways [15]. 
 
CONCLUSION 
As a conclusion, our study shows significantly in-
creased in the level of serum LDH and GGT in different 
stages of breast cancer patients receiving chemotherapy 
with or without metastasis. A rapid increase in malig-
nant cells turn over, oxidative stress and organ toxicity 
due to chemotherapy modulated the LDH, GGT expres-
sion level in blood circulation. These non-specific en-
zyme markers can be routinely used for diagnosing 
breast cancer, detecting metastasis and monitoring the 
cancer progression and treatment. 
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